Table 1.
Baseline characteristics of the study populations tested for anti-Saccharomyces cerevisiae IgG and IgA antibodies. Unless otherwise indicated values are numbers of patients (%)
| Study population | Crohn’s disease (n = 66) | Ulcerative colitis (n = 29) | Healthy controls (n = 18) | IBS patients (n = 10) |
| Age, yr | ||||
| Mean±SD | 38±16 | 37±15 | 40±13 | 57±13 |
| Range | 14-82 | 16-78 | 17-74 | 41-81 |
| Male sex | 32 (48) | 15 (52) | 10 (56) | 6 (60) |
| Disease location | ||||
| Colonic | 58 (88) | 29 (100) | ||
| Ileal | 45 (68) | |||
| Upper gastrointestinal involvement | 3 (5) | |||
| Presence of fistulae | 15 (23) | 1 (3) | ||
| Extraintestinal manifestations | 4 (6) | 0 (0) | ||
| Medical therapy | ||||
| Azathioprine | 22 (33) | 9 (31) | ||
| Infliximab | 5 (8) | 3 (10) | ||
| 5-ASA compounds | 4 (6) | 11 (38) | ||
| Methotrexate | 4 (6) | 0 (0) | ||
| Oral steroids | 29 (44) | 15 (52) | ||
| None of the above | 19 (29) | 7 (24) |